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Abstract
Background: Silver nanoparticles (AgNPs) are an important class of nanomaterials used as antimicrobial agents for
a wide range of medical and industrial applications. However toxicity of AgNPs and impact of their physicochemical
characteristics in in vivo models still need to be comprehensively characterized. The aim of this study was to
investigate the effect of size and coating on tissue distribution and toxicity of AgNPs after intravenous
administration in mice, and compare the results with those obtained after silver acetate administration.
Methods: Male CD-1(ICR) mice were intravenously injected with AgNPs of different sizes (10 nm, 40 nm, 100 nm),
citrate-or polyvinylpyrrolidone-coated, at a single dose of 10 mg/kg bw. An equivalent dose of silver ions was
administered as silver acetate. Mice were euthanized 24 h after the treatment, and silver quantification by ICP-MS
and histopathology were performed on spleen, liver, lungs, kidneys, brain, and blood.
Results: For all particle sizes, regardless of their coating, the highest silver concentrations were found in the spleen
and liver, followed by lung, kidney, and brain. Silver concentrations were significantly higher in the spleen, lung,
kidney, brain, and blood of mice treated with 10 nm AgNPs than those treated with larger particles. Relevant toxic
effects (midzonal hepatocellular necrosis, gall bladder hemorrhage) were found in mice treated with 10 nm AgNPs,
while in mice treated with 40 nm and 100 nm AgNPs lesions were milder or negligible, respectively. In mice
treated with silver acetate, silver concentrations were significantly lower in the spleen and lung, and higher in the
kidney than in mice treated with 10 nm AgNPs, and a different target organ of toxicity was identified (kidney).
Conclusions: Administration of the smallest (10 nm) nanoparticles resulted in enhanced silver tissue distribution
and overt hepatobiliary toxicity compared to larger ones (40 and 100 nm), while coating had no relevant impact.
Distinct patterns of tissue distribution and toxicity were observed after silver acetate administration. It is concluded
that if AgNPs become systemically available, they behave differently from ionic silver, exerting distinct and size-
dependent effects, strictly related to the nanoparticulate form.
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Background
Silver nanoparticles (AgNPs) are an important class of
nanomaterials characterized by sizes ranging approxi-
mately from 1 to 100 nm: these small dimensions result in
a high surface area to volume ratio determining unique
chemical, physical and biological properties different from
those of bulk material with the same composition [1].
Nowadays, AgNPs are the most common nanomaterial
found in consumer products (including cosmetics, textiles,
food boxes, sprays), appliances (refrigerators, washing
machines) and medical applications (wound dressings,
medical devices, drug-delivery systems, bio-sensing and
imaging methods) [2–5]. The widespread application of
AgNPs is mainly related to the renowned antimicrobial
activity of silver, whether ionic or nanoparticulate [6, 7].
However, extensive use of AgNPs may lead to environ-
mental contamination and human exposure by inhalation,
dermal and oral routes, raising concerns about their po-
tential environmental impact and toxicity [4].
The majority of toxicity studies on AgNPs have been per-
formed on bacteria, cell lines, and non-mammalian animal
species, with still comparatively limited information avail-
able from in vivo studies [1, 8]. In vitro studies revealed dis-
tinct (but not necessarily mutually exclusive) mechanisms
of toxicity of AgNPs, including 1) ROS generation, with
subsequent oxidative stress; 2) interaction with cellular pro-
teins and enzymes by binding to free thiol groups; and 3)
mimicry of endogenous ions (e.g. calcium, sodium, or
potassium) leading to ionoregulatory disturbances [1].
These mechanisms lead to cytokine production, cellular
damage, and eventually apoptosis or necrosis. Numerous
in vitro studies have demonstrated that the cytotoxic and
genotoxic effects of AgNPs are size- and dose-dependent,
as well as coating- and cell type-dependent [9–14].
In vivo studies in rodents (rats, mice, guinea pigs) and
occasionally in non-rodents species (pigs) have been
carried out, using different routes of exposure, in the at-
tempt to characterize kinetics, tissue distribution and
toxicity of AgNPs [15–26]. Compared to the general
consensus of in vitro studies, the results of the in vivo
studies are controversial regarding the onset of adverse
effects after AgNPs administration. Some of these stud-
ies indicate that AgNPs may have toxic effects on liver,
lung, intestine, nervous and immune systems, either
after single or repeated administration, and following
different routes of exposure [15–17, 22, 23, 26]. How-
ever, other studies found no relevant adverse effects
[19–21, 24]. These contradictory results may depend on
the high variability of the tested AgNPs, in terms of
source (generated in the laboratory or commercially
available materials), size, dispersion state, coating, and
concentration (i.e. number of particles and silver mass).
Also, the animal species, strain, sex, age, and the overall
experimental design (dose, exposure time, end points for
sampling) may have an impact on the outcome of the
study [21].
With the effort to standardize and compare in vivo
experiments, as well as to properly correlate nanoparticles’
properties with their in vivo effects, a prior and rigorous
physicochemical characterization of AgNPs is required
[27]. In particular, the assessment of size, monodispersity,
and aggregation is fundamental for a comprehensive un-
derstanding of their biological effects. However such mea-
surements, albeit fundamental, are not sufficient for fully
predicting nanotoxicological effects, likely because of ef-
fects related to the still poorly understood behavior of
nanoparticles in the biological milieu. Indeed, AgNPs after
injection readily interact with blood components (pro-
teins, lipids, etc.), forming on their surface a biomolecular
corona that influences the biological interactions of nano-
particles and cellular uptake [28]. In vivo toxicological
studies are thus considered critical for correlating the
physicochemical properties of nanoparticles with their
effects in living systems [29]. However, only very few
in vivo studies have been performed so far to evaluate the
role of size and coating of AgNPs, and based on these
studies tissue distribution and toxicity appeared to be con-
sistently size-dependent, whereas the effect of coating was
less obvious and only observed in the lung [21, 30–33]. In
addition to influencing the formation of the biomolecular
corona, size and coating are critical factors affecting the
release of silver ions from AgNPs. There has been much
debate in the literature regarding whether the adverse
effects caused by AgNPs are mediated by the release of sil-
ver ions [34]. Although it is generally accepted that dissol-
ution of AgNPs does account for at least a degree of
toxicity observed under AgNP exposure, it appears that ef-
fects cannot be fully attributed to the measured dissolved
fraction of silver especially for the smaller particles
(≤10 nm), which proved to be more toxic than predicted
on the basis of silver ion release [35, 36].
In view of the need to improve the understanding of
the impact of physicochemical characteristics of AgNPs
in in vivo models, the aim of this study was to investi-
gate the effect of the size and coating on tissue distribu-
tion and toxicity of AgNPs and compare the results with
those obtained after administration of silver ions, in the
form of silver acetate. Since this study was not intended
to mimic human exposure scenarios, to avoid limited
systemic exposure due to the cellular barriers present in
the skin, gastrointestinal tract and lungs, we used intra-
venous (IV) administration of AgNPs and ionic silver to
evaluate their potential systemic toxicity. The study
design included a thorough characterization of AgNPs
suspensions before use, assessment of tissue distribution
by measuring silver concentrations in blood and main
organs, and histopathological examination to evaluate
the presence of adverse effects and silver localization.
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Results and discussion
Physicochemical characterization of silver nanoparticles
Commercial AgNPs with a nominal size of 10, 40 and
100 nm were tested in this study. Citrate (CT)- and poly-
vinylpyrrolidone (PVP)-coated AgNPs were investigated
to probe the effect of surface stabilizing agents. Details
provided by the manufacturer on the physico-chemical
properties of the studied AgNPs are reported in Table 1.
The particles were thoroughly characterized before the in-
vestigation of their toxicological effects in vivo and their
accordance to manufacturer’s specifications assessed. A
rigorous characterization of the test dispersions is pre-
requisite to produce data that can help provide scientific
answers to regulatory issues, which are impelling for a
widely used nanomaterial type such as AgNPs.
Three different techniques were employed, namely
Dynamic Light Scattering (DLS), UV-visible (UV–Vis)
spectroscopy, and Transmission Electron Microscopy
(TEM). First, the hydrodynamic diameter of the particles
and their possible aggregation when suspended in the
testing medium were evaluated by DLS. The results are
summarized in Table 2. Monomodal distributions were ob-
served for 40 nm and 100 nm AgNPs, coated with both CT
and PVP. The 10 nm AgNP-CT and 10 nm AgNP-PVP
suspensions showed multimodal distributions. In particular,
the peaks at 18.1 and 19.6 nm were indicative of isolated
nanoparticles in 10 nm AgNP-CT and 10 nm AgNP-PVP,
respectively, while larger peaks in both samples suggested
the possible presence of aggregates with variable dimen-
sions. However, these large peaks were still detected by
DLS even after filtration (0.22 μm pore size), thus indicating
their dynamic nature.
To further investigate the intrinsic features of the
putative aggregates detected in 10 nm AgNPs, UV–Vis
spectroscopy measurements were performed. AgNPs
exhibit a characteristic absorbance maximum in the visible
range due to the surface plasmon resonance (SPR) effect
[37]. Notably, optical properties of AgNPs are closely re-
lated to their morphology, therefore UV–Vis spectroscopy
is able to detect any change in size/shape as well as the
presence of aggregates. The UV–Vis results are shown in
Table 2. The correspondence between the optical properties
given by the manufacturer and those measured in our la-
boratory appeared satisfactory; in particular, no decrease in
the maximum absorbance value (Hmax) was observed, indi-
cating absence of aggregates. Then, full absorbance spectra
of all samples were considered (Fig. 1). The optical density
in the 600–800 nm range, which is typical for aggregate ab-
sorption, was not detected in 10 nm AgNP-CT and 10 nm
AgNP-PVP, further demonstrating that the presence of
stable aggregates in these samples could be excluded [38].
Eventually, TEM analysis was performed to assess the
shape and primary size distribution of tested AgNPs. All
the tested AgNPs were spherical in shape (Fig. 2), and
their Feret diameter distributions were in good accord-
ance with data reported by the manufacturer (p > 0.05 in
all cases) (Table 2).
According to these analyses, both the 10 nm AgNP-
CT and the 10 nm AgNP-PVP gave questionable DLS
results, since peaks by far larger than 10 nm were de-
tected. Similar findings were recently reported for
AgNPs with size lower than 20 nm and 15 nm [21].
Here, the absorbance spectra clearly confirmed the ab-
sence of any stable aggregate, since neither the Hmax de-
crease nor the absorbance in the 600–800 nm range
were visible. TEM analysis further confirmed the ab-
sence of aggregates. Therefore, the large peaks detected
in the DLS analyses of 10 nm AgNPs were ascribed to















(nm) (nm) (a.u.) (mean ±
SD) (nm)
(%) (mg/ml) (n° of
particles/ml)
10 nm AgNP-CT DAG1542 na 388 164.9 8.8 ± 1.7 19.6 1.03 3.5*1014 2.0 mM
citrate
7.3
10 nm AgNP-PVP DAG1823A 21.3 389 160.2 9.5 ± 1.9 7.5 1.1 2.2*1014 MilliQ
water
6.9
40 nm AgNP-CT DAG1176 53.7 411 151.1 40.6 ± 3.0 7.0 1.12 2.7*1012 2.0 mM
citrate
7.6
40 nm AgNP-PVP DAG1391 49.3 411 148.2 40.7 ± 4.1 20.2 1.1 2.7*1012 MilliQ
water
6.7
100 nm AgNP-CT DAG1186 99.8 495 49.2 99.4 ± 7.0 10.0 1.0 1.9*1011 2.0 mM
citrate
7.3
100 nm AgNP-PVP DAG1189 117.0 492 48.2 99.0 ± 5.7 5.8 1.07 1.9*1011 MilliQ
water
5.9
CT sodium citrate, PVP polyvinylpyrrolidone, na not available (not reported in the datasheet)
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dynamic aggregates, which are unstable and do not rep-
resent a problem for in vivo experiments. In conclusion,
the characterization by DLS, UV–Vis spectroscopy, and
TEM of stock AgNPs suspensions confirmed the particle
size certified by the manufacturer and their suitability
for in vivo administration.
Dissolution of silver nanoparticles in mouse serum
The presence of ionic silver in the stock suspensions of
CT-coated AgNPs as well as AgNPs dissolution upon
interaction with mouse serum was investigated by filtra-
tion on membranes with a pore size allowing discrimin-
ation of ionic silver from AgNPs. The percentage of
ionic silver in the original stock suspensions was found
to be negligible (0.002 %, 0.001 %, 0.001 % of total silver
for 10, 40 and 100 nm AgNPs, respectively). Time-
dependent dissolution of AgNPs in simulated biological
conditions is shown in Table 3. As expected, dissolution
was greater for smaller particles and increased with time;
however even for 10 nm-sized particles at 24 h, the
Table 2 Physicochemical characterization of tested AgNPs. The main findings in AgNPs characterization are reported for each tested
sample. For DLS analyses, the mean size of AgNPs is expressed in terms of hydrodynamic diameter, however this parameter is fully
informative only for samples with monomodal distributions. Accordingly, the maximum intensity peaks were also reported to
describe more comprehensively samples having multimodal distributions (i.e. 10 nm AgNP-CT and 10 nm AgNP-PVP). The pdI
provides a measure of particles uniformity. For UV–Vis analyses, the maximum wavelength (λmax, i.e. the wavelength corresponding
to the highest absorbance of AgNPs) and the maximum absorbance value (Hmax) are reported. The λmax and Hmax values were
expressed in nanometer (nm) and arbitrary units (a.u.), respectively. Finally, AgNPs size distributions expressed as Feret diameter
(mean ± SD, nm) and variation coefficient (%) were obtained from TEM analysis
BiopureTM Silver
nanoparticle
Lot N° DLS UV–Vis TEM
Mean hydrodynamic diameter Max intensity peaks pdI λmax Hmax Diameter Variation coefficient
(nm) (nm) (nm) (a.u.) (mean ± SD, nm) (%)
10 nm AgNP-CT DAG1542 np 18.1– 4046 0.258 392 163.5 8.4 ± 1.5 25.4
10 nm AgNP-PVP DAG1823A np 19.6– 111– 4292 0.343 389 163.6 10.8 ± 2.6 24.0
40 nm AgNP-CT DAG1176 40.1 49.8 0.213 412 152.6 39.3 ± 4.8 12.3
40 nm AgNP-PVP DAG1391 51.8 67.6 0.251 410 145.7 40.3 ± 5.6 13.9
100 nm AgNP-CT DAG1186 87.6 102.9 0.148 490 45.1 107.7 ± 10.5 9.8
100 nm AgNP-PVP DAG1189 104.1 119.4 0.124 491 46.8 105.5 ± 10.9 10.4
Np not provided for samples with multimodal distributions
Fig. 1 Particle characterization by UV–Vis spectroscopy: full absorbance spectra of the tested silver nanoparticles. The optical density in the 600–800 nm
range, which is typical for aggregate absorption, was not detected in any of tested AgNPs, indicating the absence of stable aggregates in these samples
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percentage of ionic silver was found to be exceedingly
low (0.005 %).
The low dissolution of AgNPs when incubated in
mouse serum is in accordance with other studies,
which put forward that following introduction into a
physiological environment the ability of AgNPs to
release Ag+ is likely inhibited due to the formation
of the protein corona [39]. Interaction of protein
thiol groups with the charged surface of AgNPs in a
medium with a high ionic strength is at the basis of
the sulfidation process that leads to an extensive de-
crease of the dissolution rate in vitro, causing also
the formation of nanobridges between particles, and
has the potential to stabilize them in vivo [40]. For-
mation of the protein corona decreases the extracel-
lular dissolution of AgNPs leading to cellular uptake
of particles, which may lose the corona after intern-
alization resulting in an exacerbated release of Ag
ions and toxicity [39].
Dissolved silver ions are likely to immediately react
with chlorine in serum to form AgCl [41]. On the
other hand, it cannot be ruled out that a minor part
of the released silver ions might have been complexed
with high affinity S-containing proteins and thus been
excluded by the membrane used, leading to a possible
underestimation of the level of released Ag+ [42].
However, even though the method used for studying
particle dissolution may have not provided an entirely
accurate measure of ionic silver formation in physio-
logical conditions – all available methods have some
limitations in this respect [43] – it clearly shows that
extracellular dissolution of the AgNPs used in this
study is very limited and animals dosed with AgNPs
were internally exposed to particulate and not ionic
silver.
In vivo study
Mice were intravenously (IV) injected with CT- or PVP-
coated AgNPs of different sizes at a single dose of
10 mg/kg body weight (bw). For comparison, a group
was treated with silver acetate (AgAc), used as source of
silver ions, at a dose of 15.5 mg/kg bw, containing the
equivalent dose of 10 mg Ag/kg bw. The body weight of
each mouse was measured before treatment and at sacri-
fice. Mice were euthanized 24 h after the treatment, and
blood and organs were collected for silver quantification
and histological examination.
Fig. 2 TEM of tested silver nanoparticles. Representative transmission electron micrographs of 10, 40, and 100 nm AgNPs, CT- and PVP-coated. All
purchased particles were spherical in shape, and no stable aggregates were visible (scale bar = 100 nm)
Table 3 Time dependent dissolution of AgNPs in simulated biological conditions. Results for ionic silver are expressed as
percentage of total silver measured in the stock suspensions
BiopureTM Silver nanoparticle 5 min 10 min 60 min 24 h
10 nm AgNP-CT 0.377*10−3 0.510*10−3 0.937*10−3 5.010*10−3
40 nm AgNP-CT 0.049*10−3 0.075*10−3 0.176*10−3 1.235*10−3
100 nm AgNP-CT 0.005*10−3 0.016*10−3 0.038*10−3 0.366*10−3
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In this study, the IV route of administration was
selected in order to avoid the variability in absorption
from the different exposure sites and identify the poten-
tial target organs for distribution and toxicity of particles
of different size and coating as well as of ionic silver. Al-
though IV administration is not considered a relevant
route of exposure to AgNPs for the consumer, this route
of exposure can provide valuable information about the
in vivo behavior of AgNPs crossing the primary barriers
(skin, lung, gastrointestinal tract) and entering blood cir-
culation, or administered for clinical purposes (e.g. intra-
vascular medical devices, wound dressings, imaging,
drug delivery) [44–47]. In many studies silver was de-
tected in the main organs after exposure to AgNPs by
different routes [15, 16, 21, 25, 48, 49], but only few
studies investigated the presence of silver particles in tis-
sues after oral exposure in rats [21, 48]. Loeschner et al.
[48] found silver granules by using TEM in the same size
range of administered AgNPs in the intestine (basal lam-
ina, macrophages, connective tissue of submucosa), but
not in the liver, after oral administration of 14 nm
AgNPs and AgAc (9 mg/kg b.w. of silver. Another study
[21], by using single particle ICP-MS, revealed the pres-
ence of NPs in the examined organs (gastrointestinal
tract, liver, spleen, lungs) after oral administration of
15–20 nm AgNPs (90 mg/kg b.w) and AgNO3 (9 mg/
kg). In both studies, nanoparticles were found also in the
group treated with Ag+, indicating that nanoparticles
can be formed in vivo from soluble silver. Even though
there is still little information on the ability of AgNPs to
be absorbed, and distribute systemically after dermal
application, inhalation, or ingestion, a definite conclu-
sion about the complete dissolution of AgNPs before
reaching the blood circulation or within the blood can-
not be drawn as well, leaving open the question about
the potential effects of AgNPs in case they enter (even
partially) blood circulation.
A dose of 10 mg/kg bw was chosen since it was in
the range of doses used in previous IV studies without
eliciting relevant adverse effects in animals [22, 23, 30,
31, 50]. A dose of 10 mg/kg bw in mice is equivalent
to a human dose of 0.81 mg/kg bw, corresponding to
approximately 50 mg for a human of 60 kg, according
to guidelines for dose translation from animals to
humans [51].
Animal behavior, body and organ weights
Immediately after administration of AgNPs and AgAc
and during the following hours, all mice appeared
healthy and no abnormal behavior was observed. How-
ever, 24 h after the treatment two mice (one mouse
treated with 10 nm AgNP-CT and another one treated
with 10 nm AgNP-PVP) were found dead. Complica-
tions related to the injection procedure or formation of
large aggregates after administration were reasonably
ruled out given the delayed onset of mortality and re-
sults of later histopathological evaluation (i.e. absence of
thromboembolic lesions associated with silver aggre-
gates). At sacrifice, no significant differences in body
weight gain and organ weights were recorded between
CT- and PVP-coated AgNPs of the same size (Additional
file 1: Table S1). In mice treated with 10 nm AgNPs a
significant difference in percentage of weight loss and
relative spleen weight were observed compared to con-
trol and 40 and 100 nm AgNP-treated mice (Table 4).
No other significant differences were observed in relative
organ weights between treated and control mice.
Tissue distribution and localization of silver
Distribution and localization of silver in the different or-
gans 24 h after IV exposure to CT- and PVP-coated
AgNPs of three different sizes, and AgAc, were evaluated
using two distinct but complementary approaches, i.e.
inductively coupled plasma mass spectrometer (ICP-MS)
and autometallography (AMG) staining. ICP-MS was
used to quantitatively measure the total silver concentra-
tion in spleen, liver, lung, kidney, brain, and blood, while
AMG was used to qualitatively assess silver localization
within the sampled organs.
In the control group, silver was present at back-
ground levels as shown by ICP-MS data for the exam-
ined organs (Additional file 1: Table S2). In the treated
animals, at 24 h after administration the silver concen-
tration in blood was drastically reduced in all groups
compared to the peak concentrations expected on the
basis of the administered dose, in agreement with
Table 4 Body weight gain and relative organ weight (%) after IV administration of 10 mg silver/kg. Data are expressed as means ±
SD
Group n Body weight gain Spleen Liver Lung Kidney Brain
Control 3 −3.3 ± 5 0.45 ± 0.1 6.61 ± 0.8 0.66 ± 0.0 1.80 ± 0.2 1.77 ± 0.1
10 nm AgNP 6 −12.1 ± 4.1* 0.67 ± 0.0* 7.23 ± 1.1 0.76 ± 0.1 1.75 ± 0.1 1.81 ± 0.2
40 nm AgNP 6 −1.3 ± 2.8++ 0.54 ± 0.1++ 6.87 ± 0.6 0.65 ± 0.1 1.79 ± 0.3 1.78 ± 0.1
100 nm AgNP 6 −0.1 ± 5.0++ 0.40 ± 0.1++ 6.97 ± 0.2 0.63 ± 0.1 1.80 ± 0.1 1.65 ± 0.1
AgAc 3 −6.3 ± 3.3 0.47 ± 0.0+ 6.99 ± 0.0 0.80 ± 0.1 1.92 ± 0.2 1.78 ± 0.2
*p <0.05 vs Control; + p < 0.05 ++p < 0.01 vs 10 nm AgNP
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previous studies of kinetics performed after one single
IV administration of 120 mg/kg of 15 nm AgNPs [22]
and 0.8 mg/kg of 20, 80, and 110 nm AgNPs [30]. In
the blood of 10 nm AgNPs-treated mice silver was ap-
proximately 1.5 times and 3.5 times higher than in
mice treated with 40 nm and 100 nm AgNPs, respect-
ively (Additional file 1: Table S2). Since previous stud-
ies demonstrated a rapide decline (minutes to few
hours) of silver blood levels after IV injection of
AgNPs regardless of nanoparticle size [22, 30, 50], the
greater silver concentration of 10 nm AgNPs-treated
mice 24 h after exposure might indicate an increased
and earlier redistribution of silver from organs to
blood in the case of 10 nm AgNPs compared to larger
ones. The results obtained for 10 nm AgNPs are in
agreement with those of a IV study on CT-coated
AgNPs having a similar size (8 nm), administered to
rats at the same dose of the present study (10 mg/kg
bw); after an initial decrease (up to 4 h post injection)
blood silver levels increased again and did not de-
crease during the experimental period until 96 h [50].
For all particle sizes, regardless of their coating, the
highest silver concentrations were found in the spleen and
liver, followed by lung, kidney and brain (Fig. 3, and
Additional file 1: Figure S1). These results are in line with
previous studies that investigated tissue distribution of
AgNPs 24 h after IV administration [22, 30, 50]. When
considering the percentage of the administered silver dose
recovered after administration, for all tested AgNPs
approximately 40 % of the administered dose was found in
the liver, which resulted to be the main target organ of sil-
ver distribution, followed by spleen, lung, kidney, and
brain (Table 5). Most of the silver that reaches the blood is
filtered by the liver and excreted into the bile [50], while
the remaining circulating particles distributed to organs
containing large numbers of phagocytic cells, such as liver,
spleen, and lung, which are devoted to clearing foreign
body particles from the circulating blood. The role of
macrophages in general, and Kupffer cells in particular, in
clearance and accumulation of nanoparticles was the same
observed after intravenous administration of other metal-
lic nanoparticles (e.g. gold NPs) [52, 53].
With exception of the liver, where similar silver con-
centrations were identified regardless of the source of
administered silver (AgNP or silver ions), in the other
examined organs silver concentrations were higher in
mice treated with 10 nm AgNPs (including both CT-
and PVP-coated particles) than in mice treated with
larger particles (40 nm, 100 nm), and concentrations de-
creased with increasing size of AgNPs. Since the silver
concentrations found in the brain and kidney were com-
parable or lower than those found in the blood, silver
contribution of residual blood contained in these organs
cannot be completely ruled out.
As regards the role of coating on silver tissue dis-
tribution, no significant differences were found be-
tween CT- and PVP-coated AgNPs of the same size,
in line with previous studies [21]. However, Principal
Component Analysis (PCA) highlighted a trend of
CT-coated 10 nm AgNPs to cluster separately from
PVP-coated 10 nm AgNPs (right side of the first
Principal Component, PC1) likely due to the higher
silver concentrations of the 10 nm AgNP-CT in
spleen, lungs, liver, and, to a lesser extent, in kidneys
compared to 10 nm AgNP-PVP (Additional file 1:
Figure S2). PCA thus revealed that the coating might
have a potential effect of on tissue distribution at
least for the smallest (10 nm) AgNPs.
Silver localization within organs was evaluated his-
tologically. In H&E stained sections intracytoplasmic
Fig. 3 Silver tissue concentration after IV administration of AgNPs and AgAc in mice. Data are expressed as means ± SD. Statistical significance: a = p< 0.05;
b = p< 0.01 vs 10 nm
Recordati et al. Particle and Fibre Toxicology  (2016) 13:12 Page 7 of 17
black granular pigment was multifocally (and often
barely) visible in the liver (along the sinusoids), spleen
(marginal zone and red pulp), and lungs (alveolar
septa) of all AgNP-treated mice, but not in AgAc-
treated mice (Additional file 1: Figure S3).
The tissue localization of silver was better detailed
after AMG staining (Fig. 4), which enhances the silver
present within the tissues, providing a rapid, cost-
effective histochemical means of detecting the distribu-
tion of silver within organs [54]. In AgNP-treated mice,
Table 5 Percentage of recovered silver dose in mice after IV administration of 10 mg silver/kg. Data are expressed as means ± SD
Group n Spleen Liver Lung Kidney Brain
10 nm AgNP-CT 3 6.6 ± 1.2 52.0 ± 4.7 4.2 ± 1.1 0.5 ± 0.1 0.056 ± 0.015
10 nm AgNP-PVP 3 5.3 ± 1.0 41.1 ± 2.3 1.5 ± 1.2 0.4 ± 0.1 0.049 ± 0.016
40 nm AgNP-CT 3 3.6 ± 1.1 46.1 ± 2.5 0.5 ± 0.1 0.1 ± 0.1 0.037 ± 0.007
40 nm AgNP-PVP 3 3.1 ± 1.1 45.5 ± 1.9 0.3 ± 0.1 0.2 ± 0.0 0.035 ± 0.009
100 nm AgNP-CT 3 2.7 ± 0.4 36.7 ± 0,3 0.5 ± 0.1 0.1 ± 0.0 0.029 ± 0.004
100 nm AgNP-PVP 3 2.5 ± 0.6 45.7 ± 1.1 0.2 ± 0.0 0.1 ± 0.0 0.028 ± 0.003
AgAc 3 0.6 ± 0.2 42.6 ± 4.5 0.3 ± 0.1 2.4 ± 0.6 0.064 ± 0.011
Fig. 4 Histological evaluation of silver tissue localization by AMG. Representative images of spleen, liver, kidney, and lung (scale bar = 20 μm),
from vehicle- (control), AgNP (10 nm, 40 nm, 100 nm), and AgAc-treated mice. In the spleen, silver was localized within the cytoplasm of macrophages in
the marginal zone of the white pulp (WP) and in the red pulp (RP). In the liver, the cellular localization of silver varied depending on the size of the AgNPs.
In 10 nm AgNP-treated mice, silver was present in the cytoplasm of Kupffer cells (arrowhead), sinusoidal endothelial cells (arrow) and hepatocytes (*).
In 40 nm AgNPs-treated mice, silver was localized in the cytoplasm of portal endothelial cells (*), sinusoidal endothelial cells (arrow) and Kupffer cells
(arrowhead). In 100 nm AgNPs-treated mice, most of silver was concentrated in the cytoplasm of Kupffer cells (arrowhead). In AgAc-treated mice, silver
was present in the cytoplasm of hepatocytes (*), and Kupffer cells (arrowhead). In the kidney, occasional silver-containing cells were observed in the
renal interstitium of 10 nm AgNP treated-mice (arrowhead), and large amounts of silver were identified in necrotic tubules of AgAc-treated mice
(arrowhead). In the lung, scattered silver-containing cells were found in the alveolar septa of 10 nm and 40 nm AgNP-treated mice
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regardless of the particle size and coating, the organs
showing the greatest silver accumulation were the spleen
and liver in agreement with the results of total silver
quantification obtained by ICP-MS. Occasionally, en-
hanced silver clusters were found in the lung and occa-
sionally in the kidney (mainly in 10 nm AgNPs-treated
mice), and none in the brain. In the spleen, silver was lo-
calized within the cytoplasm of macrophages in the mar-
ginal zone of the white pulp and in the red pulp, and
occasionally within splenic endothelial cells. In the liver
most of the silver was found in the cytoplasm of Kupffer
cells along the sinusoids, and occasionally within sinus-
oidal and portal endothelial cells, and more rarely within
hepatocytes, in accordance with previous studies [23, 31,
55]. A sort of size-dependent pattern of silver distribu-
tion in the liver was observed, suggesting that silver
uptake by Kupffer cells is almost exclusive after adminis-
tration of 100 nm AgNPs, while administration of 10 nm
and 40 nm AgNPs resulted in silver uptake also by endo-
thelial cells, and hepatocytes, in addition to Kupffer cells.
Only occasionally, the silver was identified in the gall
bladder of 10 nm AgNP-treated mice (within gall blad-
der epithelial cells and endothelial cells of blood vessels).
In the lung, scattered silver containing cells were found
in the alveolar septa, either within the capillaries or the
interstitium. In the kidney, only in mice treated with
10 nm AgNPs there were occasional silver-containing
cells in the glomerular tufts, and renal interstitium,
morphologically consistent with circulating leukocytes
(monocytes) that were also occasionally observed in the
other examined organs. No enhanced silver clusters were
identified in the brain sections of treated mice. This lack
of histological identification of silver in the brain is con-
sistent with the very small concentrations of silver
detected in this organ by ICP-MS.
In mice treated with AgAc silver concentrations deter-
mined by ICP-MS were similar in the liver and brain,
but significantly lower in the spleen and lung, and higher
in the kidney compared to mice treated with 10 nm
AgNPs (Fig. 3). Differently from AgNP-treated mice, no
black granular deposits (reminiscent of silver) were
found throughout the examined tissues stained with
H&E. In AMG stained sections, silver enhanced clusters
were identified in the liver (within Kupffer cells and
hepatocytes), spleen (marginal zone and red pulp), and
kidney (at level of degenerated/necrotic tubules) (Fig. 4).
No silver was identified in the lung and brain. Organs
from AgAc-treated mice showed higher values than
those from the control and AgNP-treated mice on PC2,
due to the higher silver concentration in the kidney
(Additional file 1: Figure S2). Overall these results sug-
gest that silver ions have a different biodistribution pat-
tern, and likely also of cell uptake, and excretion (i.e.
enhanced role of renal excretion in addition to biliary
excretion) compared to nanoparticles. This difference in
kinetics was reflected also by the identification of dis-
tinct target organ of toxicity for silver ions and AgNPs,
as discussed below.
Immunostaining of sections with IBA1 (a pan-
macrophage marker) further confirmed that most of
silver-containing aggregates were present within the
cytoplasm of Kupffer cells in the liver, in all AgNP-
treated groups (Fig. 5). The amount and size of silver-
containing aggregates within macrophages decreased
with decreasing size of AgNPs. In 10 nm AgNPs-
treated mice only scattered and very small aggregates
were found throughout the liver, while no visible
silver-containing aggregates were found in the liver of
AgAc treated mice, despite the identification of silver
by AMG staining within Kupffer cells and hepatocytes.
This result may suggest a different intracellular behav-
ior of silver depending on its form and size.
Since ICP-MS does not provide information about the
soluble or particulate form of silver detected within the
tissue, it is not possible to know whether the silver-
containing aggregates identified histologically in this study
were composed of silver nanoparticles or silver salts
formed upon interaction of silver ions with sulphur and
selenium, as previously described in the intestine of rats
following oral administration of AgNPs and AgAc [48], or
in the skin of patients with argyria [56, 57]. Additional
analyses, e.g. employing TEM with energy dispersive x-ray
spectroscopy (EDX), and Single Particle ICP-MS (not for
the 10 nm AgNPs, which are below the size detection
limit of the technique) should be taken into consideration
in future studies, to assess the composition and subcellu-
lar localization of silver within tissues, allowing to better
understand the intracellular fate of AgNPs and/or silver
ions.
Toxicity
Two mice out of six were found dead 24 h after treat-
ment with 10 nm AgNPs. No relevant gross changes
were observed in the examined mice, except for a mod-
erate splenomegaly in mice treated with 10 nm AgNPs.
Histological AgNP-related lesions were observed in the
spleen, liver, and gall bladder of AgNP-treated mice
(Fig. 6). No relevant differences were found between
CT- and PVP-coated particles of the same size. Overall
the prevalence and severity of lesions (in particular those
involving liver and gall bladder) were size-dependent,
with mice treated with 10 nm AgNPs most frequently
and severely affected compared to 40 nm and 100 nm
AgNP-treated mice that had milder or negligible lesions,
respectively (Tables 6 and 7). Splenic hyperemia was
present in all mice treated with AgNPs, but only in mice
treated with 10 nm-sized particles it was particularly
pronounced, and thus likely responsible for inducing
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splenomegaly, as well as the increased relative spleen
weight observed in this group. Mice treated with 10 nm
AgNPs were affected by diffuse and severe midzonal
hepatocellular necrosis and hemorrhage, multifocal peri-
biliary microhemorrhages, occasional portal vein endo-
thelial damage (i.e. endothelial sloughing, subendothelial
hemorrhages, intraluminal fibrin thrombi) (Additional
file 1: Figure S4), and diffuse mural and intraluminal
hemorrhage of the gall bladder. Among mice treated
with 40 nm AgNPs only one out of six had early peripor-
tal coagulative necrosis, scattered hepatic single cell ne-
crosis, and gall bladder severe mural and intraluminal
gall bladder hemorrhage. In the other mice treated with
40 nm AgNPs, the hepatic lesions were not observed
and gall bladder lesions were milder, usually consistent
with mural hyperemia and/or edema. Mice treated with
100 nm AgNPs had only occasional and mild gall blad-
der mural hyperemia and/or edema. No relevant
pathological changes were observed in the lung, kidney
and brain of AgNP-treated mice, and in all the examined
organs of control mice.
A completely different pathological scenario was ob-
served after administration of AgAc. Hepatobiliary le-
sions were not observed, whereas a marked acute renal
tubular necrosis and apoptosis with intraluminal accu-
mulation of hyaline casts was found in all treated mice.
Presence of renal lesions, associated with identification
of silver in the affected renal tubules and relevant silver
concentrations in the kidney of AgAc-treated mice indi-
cates that dissolved silver ions resulted in an increased
renal silver distribution compared to AgNPs, and that
renal lesions were likely secondary to the renal excretion
of silver.
Although liver is considered one of the most important
target organs for AgNPs, given its capacity of AgNP accu-
mulation and its role in biliary excretion of AgNPs [49], so
Fig. 5 Localization of silver in the liver evaluated by confocal microscopy. Representative images of liver (scale bar = 20 μm), from vehicle- (control),
AgAc, and CT- and PVP-coated AgNP (10 nm, 40 nm, 100 nm)-treated mice. Aggregates of silver (green) are found within the cytoplasm of Iba-1+
Kupffer cells (red) (white arrows) only in AgNP-treated mice. Rarely, small numbers of silver aggregates are found outside Kupffer cells (yellow arrow),
most likely in the cytoplasm of endothelial cells or hepatocytes. Nuclei are counterstained with DAPI (cyan)
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Fig. 6 Histological evaluation of adverse effects after single IV administration of AgNPs and AgAc in mice. Representative images of spleen (scale bar =
500 μm), gall bladder (scale bar = 500 μm), liver (scale bar = 50 μm), and kidney (scale bar = 50 μm) from vehicle- (control), AgNP (10 nm, 40 nm, 100 nm),
and AgAc-treated mice. No relevant changes were present in the examined organs of control mice. In the spleen, a severe hyperemia of the red pulp was
present in 10 nm-treated mice (*). In the gall bladder, severe intraluminal (*) and mural (arrowhead) hemorrhages were found in 10 nm AgNPs-treated
mice, and in a single mouse treated with 40 nm AgNPs, while in 100 nm-treated mice only mild mural edema and hyperemia were occasionally evident.
In the liver, in 10 nm AgNP-treated mice marked midzonal hepatocellular necrosis (*) and hemorrhages (arrowhead) were present, while in 40 nm-treated
mice only occasional single cell necrosis (arrowhead, and inset) and early signs of coagulative periportal necrosis (*) were found (PV = portal vein). In the
kidney, in AgAc-treated mice marked tubular necrosis (arrowhead) with intraluminal hyaline casts (*) were present
Table 6 Prevalence of histopathological lesions in mice following IV exposure to 10 mg silver/kg. Data are expressed as number of
mice with lesions/total number of examined mice per group (%)
Group Spleen Liver Gall bladder Lung Kidney Brain
Control 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
10 nm AgNP-CT 3/3 (100 %) 3/3 (100 %) 3/3 (100 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
10 nm AgNP-PVP 3/3 (100 %) 3/3 (100 %) 3/3 (100 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
40 nm AgNP-CT 3/3 (100 %) 1/3 (33 %) 2/3 (67 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
40 nm AgNP-PVP 2/3 (67 %) 0/3 (0 %) 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
100 nm AgNP-CT 1/3 (33 %) 0/3 (0 %) 2/3 (67 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
100 nm AgNP-PVP 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
AgAc 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 3/3 (100 %) 0/3 (0 %)
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far hepatotoxic effects of AgNPs have been inconstantly
demonstrated in in vivo studies, either after IV, oral, or in-
halation exposure to AgNPs. In particular, hepatotoxicity
was generally recognized through changes in the blood
biochemical parameters of liver function (such as ALT,
AST, ALP, and cholesterol) [16, 17, 23, 58], while only oc-
casionally mild histopathological changes were reported,
such as biliary hyperplasia, fibrosis, hepatocellular vacu-
olar degeneration, and rarely necrosis [15, 16, 22]. The
lack of overt hepatic histopathological lesions in previous
studies that used small-sized particles could be related to
a poor dispersion of AgNPs in the administered suspen-
sions [22], since agglomeration of particles can affect bio-
availability by reducing the rate of degradation or cell
uptake [8]. According to our characterization of AgNPs,
we administered well-dispersed 10 nm-sized particles. An-
other aspect is that most of earlier in vivo studies of distri-
bution and toxicity of AgNPs have been performed in rats
and not in mice. Further investigation should be per-
formed in order to assess whether there is a different sen-
sitivity between these two species.
In addition to the severity of the hepatic lesions found
in mice treated with 10 nm AgNPs, also the pattern of he-
patocellular necrosis observed is very unusual. Midzonal
necrosis is the least common histologic pattern of hepato-
cellular necrosis following exposure to hepatotoxicants
[59]. Because hepatocytes are extremely variable in their
metabolic capacity and oxygen tension, midzonal necrosis
of hepatocytes is presumably dictated by an unique sus-
ceptibility of these hepatocytes based on their location
within the hepatic lobule [60]. The hemorrhage observed
in the gall bladder of mice treated with 10 nm AgNPs and
occasionally in mice treated with 40 nm AgNPs is another
very unusual finding. We can speculate that gall bladder
mural hemorrhage, as well as portal peribiliary hemor-
rhages, could be the result of endothelial damage second-
ary to a massive elimination of AgNPs in the bile, which is
considered the main route of silver excretion following IV
administration of AgNPs [31, 50]. The hypothesis of
particle-induced endothelial damage is further corrobo-
rated by the presence of endothelial damage found in the
intrahepatic branches of portal veins that may have oc-
curred after intestinal re-absorption of AgNPs excreted in
the bile. Another concurrent factor in the pathogenesis of
gall bladder hemorrhage could be the anti-platelet proper-
ties of AgNPs that may have impaired a prompt clotting
response [61].
In this study relevant size-dependent adverse effects
were observed 24 h after IV administration of AgNPs in
mice. First of all, and differently from previous studies
where AgNPs were administered IV (up to a dose of
120 mg/kg bw) [22, 23, 30, 31, 50], mortality was observed
in 2 out of 6 mice treated with the smallest particles
(10 nm AgNPs), regardless of the coating. The most strik-
ing finding was the marked hepatotoxicity demonstrated
by 10 nm AgNPs (both CT and PVP-coated), associated
with a massive hemorrhage of the gall bladder. These le-
sions (in particular the hemorrhage) were especially severe
in the two mice found dead, and can thus be regarded as
the most likely cause of death. Of note, administration of
AgNPs of different sizes and silver acetate resulted in
similar liver content of total silver (as determined by ICP-
MS), indicating that hepatobiliary toxicity induced by
10 nm AgNPs was not related to the mass of silver con-
tained in the liver, but rather it was imputable to their
small size. Size-dependent toxicity of AgNP was previ-
ously demonstrated in in vitro [11, 13, 14, 36], as well as
in in vivo studies using the respiratory route of
Table 7 Grading of most relevant histopathological lesions in mice after IV administration of 10 mg silver/kg. Results are expressed
as median score per group (range) (n = 3)













Control 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0)
10 nm AgNP-
CT
4 (3–4) 2 (1–4) 1 (0–4) 2 (2–4) 2 (2–3) 0 (0–0)
10 nm AgNP-
PVP
4 (2–4) 2 (1–4) 2 (0–4) 2 (1–4) 3 (3–4) 0 (0–0)
40 nm AgNP-
CT
0 (0–1) 0 (0–1) 0 (0–0) 1 (1–4) 2 (2–3) 0 (0–0)
40 nm AgNP-
PVP
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 2 (1–2) 0 (0–0)
100 nm
AgNP-CT
0 (0–0) 0 (0–0) 0 (0–0) 1 (0–1) 0 (0–1) 0 (0–0)
100 nm
AgNP-PVP
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0)
AgAc 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 4 (3–4)
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administration [32, 33]. Our results further support the
importance of nanoparticle size for AgNP toxicity in vivo.
Release of silver ions following oxidation of particle sur-
face after administration of AgNPs is believed to consti-
tute the major mechanism contributing to AgNP toxicity
and since dissolution increases with decreasing size of
AgNPs [33], this appears to be the determinant of the
enhanced toxicity of smaller AgNPs compared to larger
ones. The most obvious explanation for increased dissol-
ution of smaller particles, compared to an equivalent mass
concentrations of larger particles, is their higher number
(in this study, the number of administered 10 nm AgNPs
was about 100 fold greater compared to 40 nm AgNPs)
and consequent larger surface area per unit mass. The re-
sults of our study however demonstrated that systemic
availability of silver ions is not responsible for the in vivo
hepatobiliary toxicity observed in mice treated with 10 nm
AgNPs, because dissolution of 10 nm AgNPs in mouse
serum was very low (0.005 %) and administration of AgAc
resulted in a distinct target organ of toxicity (kidney
instead of hepatobiliary system). Cell-type-dependent tox-
icity of silver ions and AgNPs was previously demon-
strated in in vitro studies. Furthermore, recent in vitro
studies demonstrated that toxicity of AgNPs rather than
being caused by silver ions liberated in the culture
medium is actually dependent on their intracellular release
[35, 62, 63]. According to the recently proposed general
mechanism for toxicity of metal-containing nanoparticles,
the so-called “Lysosome-Enhanced Trojan Horse effect”,
toxicity of these particles occurs after cellular uptake by
endocytosis and it is mediated by enhanced intracellular
release of ions secondary to the acidic corrosion within
lysosomes [62]. Increased toxicity of smaller AgNPs is
then explained by their increased number and reactive
surface area, resulting in increased intracellular release of
silver ions. The fact that the entry of AgNPs into cells is
size-dependent contribute to further enhance the toxic
potential of small particles, owing to their higher bioavail-
ability to cells [11, 13, 14, 35].
In our study, coating of AgNPs with CT and PVP
did not have a detectable effect on toxicity indicating
that particle size is more important than coating to
predict potential adverse effects of silver nanoparti-
cles, at least for the coatings tested herein. Coating-
dependent toxic effects were demonstrated in vitro
[9, 10], and only in the lungs in vivo [32, 33]. It can
be speculated that in in vivo studies, including ours,
coating has a minor effect, if any, as a consequence
of the formation of a corona after the adsorption of
proteins (and other biomolecules) on the surface of
particles once they enter in contact with biological
fluids [28]. The protein corona might mask the ef-
fect of the different particle coatings that is evident
in in vitro studies. This is in agreement with the
recent view that to predict the biological behavior of
nanoparticles the fingerprinting of the protein cor-
ona is more accurate than the sole characterization
of their physicochemical properties, since the protein
corona confers to nanoparticles a ‘biological identity’
that is strongly dependent but distinct from its ‘syn-
thetic identity’ [64, 65].
Conclusions
With this study, the influence of two distinct nanoparti-
cle properties, size and coating, was comprehensively
investigated in an in vivo model. We observed that tissue
distribution and toxic effects of AgNPs in mice after IV
administration are strongly size-dependent, while coat-
ing (CT or PVP) did not have a sizeable impact on tissue
distribution and toxicity. Overall, the smallest (10 nm)
particles resulted in higher silver tissue distribution and
caused overt acute adverse effects (centered on the hepa-
tobiliary tract) compared to the larger ones (40 and
100 nm). Overall, these results suggest that in the safety
assessment of silver particles the effect of size has to be
carefully considered, with a focus on small particles
(≤10 nm). Comparison with AgAc revealed a distinct
pattern of tissue distribution and toxicity between AgNP
and silver ions, indicating that the in vivo effects of
AgNPs are not attributable merely to the in vivo release
of silver ions in circulating blood but are strictly related
to the nanoparticulate form.
Methods
Characterization of silver nanoparticles
Suspensions of BioPure™ Silver Nanoparticles (AgNPs)
of 10, 40 and 100 nm in size, coated with either citrate
(CT) or polyvinylpyrrolidone (PVP), were purchased
from NanoComposix (San Diego, USA). All the sus-
pensions were supplied at a concentration of about
1.0 mg/ml. BioPure™ AgNPs were chosen because they
were guaranteed to be sterile and with an endotoxin level
lower or equal to 2.5 EU/ml. The suspending solvents of
CT- and PVP-coated AgNPs were 2.0 mM sodium citrate
and Milli-Q water (Millipore), respectively. For particle
characterization, the CT and PVP-coated AgNPs were
diluted with 2.0 mM sodium citrate (cod. W302600,
Sigma-Aldrich) buffer and Milli-Q water, respectively.
When necessary, samples were sonicated (Elmasonic S
30 H) for up to 30 s, in accordance with the manufac-
turer’s instructions. In order to prevent contamination,
measurements were run using disposable plastic cuvettes.
The AgNPs were tested immediately after their delivery
and in vivo experiments were run in the following week.
In the meanwhile, the AgNPs were stored at +4 °C, ac-
cording to manufacturer’s instructions.
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Dynamic Light Scattering (DLS)
The actual size of AgNPs in dispersion was measured by
DLS. Measurements were performed with a Malvern
Zetasizer Nano ZS90 instrument operating with a light
source wavelength of 532 nm and a fixed scattering
angle of 90°. All the nanoparticles were diluted 1:100
with the exception of 10 nm-sized AgNPs. Indeed, due
to their small size, the 10 nm AgNPs presented in-
creased absorption and lower scattering intensity com-
pared to 40 nm and 100 nm AgNPs. Accordingly, the
10 nm AgNPs were diluted 1:50. All measurements were
run at room temperature for at least three times.
UV-Visible (UV–Vis) Spectrophotometry
The UV–Vis spectra were acquired in the 300–800 nm
range using a DU730 Beckman Coulter Spectrophotom-
eter. All the nanoparticles were diluted 1:100 with the
exception of 10 nm AgNPs, which were diluted 1:200
because of their increased UV–Vis absorbance with re-
spect to larger nanoparticles. All measurements were
run at room temperature for at least three times.
Transmission Electron Microscopy (TEM)
Formvar coated copper TEM grids (cod. PE1GC300,
Pelco) were pre-treated with 20 μl of poly-L-lysine
0.01 % (w/v) (Sigma Aldrich) for 15 min. After washing
twice with MilliQ water, 3 μl of AgNPs suspensions were
deposited onto the grid for 5 min and then rinsed with
3 μl of 2-propanol (Sigma Aldrich). According to the
manufacturer’s advice, 100 and 40 nm AgNPs were used
at the concentration of 1.0 mg/ml, while 10 nm AgNPs
were diluted up to 0.1 mg/ml before use. The grids were
allowed to dry overnight at room temperature in a cov-
ered crystallizing dish. TEM (FEI Tecnai G2, Eindhoven)
images were analyzed with the ImageJ software (http://
imagej.nih.gov/ij/) to obtain the nanoparticles dimen-
sional distribution. In particular, small objects due to
background and overlapping nanoparticles were omitted
by using proper cut-off filters and Feret diameter
(intended as the larger diameter of the NP projection)
was used to evaluate the size of the particles. For each
sample, a minimum of about 250 nanoparticles was
considered.
Dissolution study
CT-coated particles were selected for this investigation
given the higher stability and lower dissolution generally
showed by PVP-coated AgNPs [66, 67]. Dissolution of
CT-coated AgNPs of 10, 40 and 100 nm was ascertained
by ultrafiltration, using a PES spin filter membrane
(Vivaspin 500, 3 kDa MWCO, Sartorius, Göttingen,
Germany) and centrifugation at 15000 g for 20 min,
followed by quantification of silver in the filtrates. The
concentration of ionic silver was measured both in the
AgNPs stock suspensions and in conditions simulating
AgNPs interaction with biological fluids. For the latter
purpose, each stock suspension was spiked to mouse
serum (Euroclone, Milan, Italy) in order to provide the
mass concentration of AgNPs of a single dose of 10 mg/
kg bw, which approximately corresponded to a 1:5 dilu-
tion (v/v) of the original AgNPs suspension. Spiked sam-
ples and serum blank were prepared in triplicate and
incubated at 37 °C under agitation for 5, 10, 60 min and
24 h. Ionic silver was assessed for each timepoint. For
ICP-MS determination of ionic silver, filtrates (prepared
in triplicate) were vigorously shaken before further dilu-
tion and analysis as described in the section “Determin-
ation of silver”. In addition to ionic silver, each stock
suspension of CT-coated AgNPs was characterized in
terms of total silver concentration and the results for
ionic silver were expressed as percentages of total silver
(AgNPs + Ag+). Samples for total silver determinations
were prepared in triplicate by dilution with acidified
(HNO3) water as necessary. In order to establish possible
sources of bias from the filtration membrane, procedural
blanks were run in parallel and the recovery of ionic sil-
ver (10 μg/L) from the filtration unit was assessed. No
silver was detected in the procedural blanks and the
average recovery of ionic silver was found to be 102.6 ±
3.8 %, showing absence of silver release/adsorption dur-
ing filtration.
Animals
Male CD-1(ICR) mice of 4–5 weeks were purchased
from Charles River (Calco, Italy). They were acclimated
to the environment for a week prior to the initiation of
the study, with free access to water and a standard pellet
diet ad libitum. The environmental conditions were set
at a temperature of 22 ± 2 °C, relative humidity of 55 ±
10 % and a 12 h light/dark cycle.
Experimental design
Mice were randomly assigned to groups of treatments.
The mice were intravenously (IV) injected into the lateral
tail vein with AgNPs of different sizes (10 nm, 40 nm,
100 nm), either CT- or PVP-coated, at a single dose of
10 mg/kg body weight (bw), and with AgAc at a single
dose of 15.5 mg/kg, corresponding to 10 mg Ag/kg bw (3
mice per group). The AgNPs suspensions were adminis-
tered to animals without any dilution. The control group
was treated with sterile water for injection. Immediately
after the treatment and the following hours, the general
health and behavior of mice were monitored. The body
weight of each mouse was measured before treatment and
at sacrifice. Mice were euthanized 24 h after the treat-
ment. The experiment was approved by an independent
Ethical Committee on Animal Experimentation (Ethical
Committee of the University of Milan, Opinion no. 81/14)
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and was performed in accordance with the Italian Laws
(D.L.vo 116/92 and following additions), which enforce
EU 86/609 Directive.
Sampling
At 24 h after IV administration mice were euthanized by
carbon dioxide inhalation. After drawing blood from the
heart, mice underwent complete necropsy. Blood, liver,
spleen, kidneys, lungs, and brain were collected for silver
quantification and histopathological examination. The
organ weight was measured and relative organ weights
(%) were calculated as wet organ weight/total body
weight. For quantification of silver, blood and a portion




Ultrapure deionized water obtained by a Milli-Q Element
System (Millipore, Molsheim, France), ultrapure grade ni-
tric acid (67–69 % v/v) (Carlo Erba Reagenti, Rodano, Italy),
ultrapure grade hydrochloric acid (32-35 % v/v) (Romil Ltd,
Cambridge, UK) and ultrapure grade hydrogen peroxide
(30 % v/v) (Merck, Darmstadt, Germany) were used
throughout. For ICP-MS measurements, silver calibrants
and rhodium solutions used were obtained from standard
certified solutions of 1 mg/ml (High Purity Standard,
Charleston, SC) by dilution with acidified (HNO3 and HCl)
water, as necessary.
Determination of total silver content
Total silver concentrations were determined in organs and
whole blood by means of a triple quadrupole inductively
coupled plasma mass spectrometer (ICP-MS). A 8800 ICP-
QQQ spectrometer (Agilent Technologies, Japan, Tokio)
equipped with an autosampler, a peristaltic pump, a Micro-
Mist glass concentric nebuliser, and operated at a RF power
of 1550 W, was used. All sample manipulations were car-
ried out in clean room conditions under a laminar flow box
(Spetec GmbH, Erding, Germany). Before ICP-MS mea-
surements, whole organs and blood were placed in Falcon
tubes and pre-digested for 5 h at room temperature with
2–4 ml HNO3, depending on the organ weight. After add-
ing 1 ml H2O2, samples were digested in a microwave sys-
tem (Milestone Ethos E microwave labstation, FKV,
Bergamo, Italy) at 90 °C for 8 h, maximum power 800 W.
After cooling, the digests were diluted by adding HCl (final
concentration 3.0 M) to promote the formation of soluble
silver complexes and prevent the precipitation of insoluble
Ag+ salts. Prior to analysis the digests were highly diluted
with 0.1 % HNO3 and the appropriate amount of HCl so as
to maintain the silver in complexed form. Measurements
were carried out on 107Ag and 103Rh, as internal standard,
by the method of external calibration. The method
detection limit ranged from 0.4 to 0.7 μg/kg, depending on
the tissue, and was 0.09 μg/l for blood.
Analytical quality control
Trueness of ICP-MS measurements was assessed by ana-
lysing the certified reference material SRM 1577c Bovine
Liver (NIST, Gaithersburg, MD, USA), with a certified
value for silver of 5.9 ± 1.6 μg/kg and the control mater-
ial Seronorm™ Trace Elements Whole Blood L-1 (SERO
AS, Billingstad, Norway) with a indicative value for silver
of 185 ± 10 ng/l, both included in every analytical batch.
The average determined silver concentrations were 6.0 ±
0.5 μg/kg (n = 6) and 179 ± 2 ng/l (n = 6) for the liver-
based and the blood-based materials, respectively, in
good agreement with the reference values. The trueness
of determinations was also assessed through spikes of
known amounts of silver in tissues and blood before
sample dissolution, giving recoveries within the range of
90-100 % with no appreciable differences between sam-
ple types.
Histopathological examination
For histological examination, liver (median lobe includ-
ing the gall bladder), spleen (apical portion), kidney (half
of the right kidney), lung (left lobe), brain (half brain,
cut along the sagittal plane) were fixed in 10 % neutral
buffered formalin for at least 48 h at room temperature,
routinely processed for paraffin embedding, sectioned at
4 μm thickness, stained with hematoxylin-eosin (H&E),
and evaluated under a light microscope. Grading of
histopathological lesions in the examined organs was
performed as follows: 0 = absence of lesions; 1 = minimal
lesions; 2 =mild lesions; 3 =moderate lesions; 4 = severe
lesions.
To analyze the tissue distribution and localization of
silver, autometallography (AMG) [42] and immunofluor-
escence were performed on serial sections. After AMG
staining, sections were counterstained with safranin O
and evaluated under a light microscope for the identifica-
tion of tissue and cellular localization of silver, visible as
black granular pigment. For immunofluorescence, liver
sections were immunostained with rabbit monoclonal
anti-IBA1 antibody (Wako Chemicals Richmond, VA,
USA, cat. No. 019-19741), a pan-macrophage marker [68].
Secondary antibody, Alexa Fluor® 555 F(ab’)2 Fragment of
Goat Anti-Rabbit IgG (H + L) (Life Technologies Europe
BV, Monza, Italy, cat. No. A-21430) was then added.
Immunofluorescently labeled sections were acquired with
the Leica TCS SP5 confocal microscope (Leica Microsys-
tems GmbH, Wetzlar, Germany). The Alexa555 fluoro-
phore was excited with the 561 nm laser line and the
emitted fluorescence (570–700 nm) acquired with a 63x/
1.4 oil immersion objective (Leica Microsystems GmbH).
Nuclei were visualized by DAPI staining (405 nm laser line
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excitation, 415–500 nm acquisition window). Silver aggre-
gates were visualized by reflection of light at 561 nm [24].
Statistical analysis
Data were analyzed using Graph Pad Prism version 5.0
(GraphPad Software, San Diego, CA). For TEM, paired
samples t-test was performed. Since the number of data
(weights and silver concentrations) obtained from in vivo
experiments was small, nonparametric tests (Kruskal-Wallis
and Mann–Whitney U test) were used to detect differences
between groups. The P-values <0.05 were considered statis-
tically significant. Data were additionally explored by Princi-
pal Component Analysis, in order to understand the
relationships among variables and their effect on data
distribution.
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